

entitled "Prognostic factors identify 3 risk groups in the LRF CLL4 trial, independent of treatment allocation." Authors: D Oscier, R Wade, Z Davis, A Morilla, G Best, S Richards, M Else, E Matutes, D Catovsky.

Information about the contributions of each person named as having participated in the study

- 1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
- D Catovsky ³Section of Haemato-oncology, The Institute of Cancer Research, Sutton, UK, d.catovsky@icr.ac.uk
 - D Oscier, Department of Haematology, Royal Bournemouth Hospital, david.oscier@rbch.nhs.uk

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): "Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: D Oscier, S Richards, D Catovsky.

3) **Design & Methods**. The following authors were responsible for specific investigations :

- E Matutes was responsible for morphological, cytogenetic and immunophenotypic review
- Z Davis, A Morilla, G Best were responsible for IGHV gene and immunophenotypic studies
- S Richards and R Wade were responsible for statistical analysis

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables:

- R Wade, M Else and D Oscier were responsible for the results, tables and figures

5) **Writing the manuscript**. The following authors were responsible for writing the manuscript:

- D Oscier
- S Richards
- M Else
- D Catovsky

6) Contributors Listed in Acknowledgments

The authors would like to thank Peter Hillmen, chair of the UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Working Group, for providing editorial assistance to the authors during preparation of this manuscript; Vasantha Babapulle and Ricardo Morilla, The Institute of Cancer Research, for conducting laboratory studies; the cytogeneticists John Swansbury and Toon Min, The Institute of Cancer Research, and Anne Gardiner and Hazel Robinson, Royal Bournemouth Hospital, for conducting a cytogenetic (FISH) review of a cohort of TP53-deleted cases. We would also like to thank the UK National Cancer Research Institute (NCRI) Chronic Lymphocytic Leukaemia Working Group for participating in this study.

Funding

The LRF CLL4 trial was supported by a core grant from Leukaemia & Lymphoma Research. Laboratory studies were supported by an educational grant from Schering Health Care (UK) and Schering AG (Germany). ME was supported by the Arbib Foundation.